New York, NY -- (SBWIRE) -- 12/18/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Banco Santander Brasil SA (ADR) (NYSE:BSBR), Advanced Semiconductor Engineering (ADR) (NYSE:ASX), Synta Pharmaceuticals Corp (NASDAQ:SNTA), Array Biopharma Inc (NASDAQ:ARRY)
Banco Santander Brasil SA (ADR) (NYSE:BSBR) showed a volume of 2.21million shares by the end of last trade whereas the average volume of the stock remained 3.55 million shares. The stock opened the session at $6.06 but then moved to $5.98. At that price, the stock showed a negative performance of -0.50%. Banco Santander Brasil SA (the Bank) is a Brazil-based bank. The Bank operates as a multiple service bank through three business segments: Commercial Bank, Global Wholesale Bank and Asset Management and Insurance. The Commercial Banking segment encompasses the entire commercial banking business (except for the Corporate Banking business managed globally using the Global Relationship Model).
Will BSBR Get Buyers Even After The Recent Rally? Find Out Here
Advanced Semiconductor Engineering (ADR) (NYSE:ASX) opened the session at $4.67 and closed the session at $4.79. The stock showed a positive performance of 4.59% in previous trading session. Traded with volume of 2.18 million shares in the prior session and the average volume of the stock remained 1.02 million shares. Advanced Semiconductor Engineering, Inc. is principally engaged in the manufacture, assembly, processing, testing and distribution of integrated circuits (ICs). The Company provides IC assembly offerings, such as dual-in-line, plated-through-hole (PTH), flip-chip, ball-grid-array (BGA), chip scale package (CSP), quad and other package offerings; test service offerings, such as front-end engineering testing,
For How Long ASX will fight for Profitability? Read This Trend Analysis report
Synta Pharmaceuticals Corp (NASDAQ:SNTA) opened the session at $4.46 and closed the session at $4.30. The stock showed a negative performance of -4.23% in previous trading session. Traded with volume of 2.16 million shares in the prior session and the average volume of the stock remained 2.22 million shares. The beta of the stock remained 3.09. Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases. As of December 31, 2011,
Why Should Investors Buy SNTA After the Recent Fall? Just Go Here and Find Out
Array Biopharma Inc (NASDAQ:ARRY) the stock decreased -1.01% and finished the session at $4.90. Traded with volume of 2.15 million shares in the prior session and the average volume of the stock remained 1.91 million shares. The beta of the stock remained 1.61. Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. The Company’s drug candidates include AMG 151, MEK162, ARRY-380, ARRY-520, ARRY-543 and ARRY-614.
Will ARRY Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)